Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
Alessandra Aiello, Andrea Coppola, Serena Ruggieri, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 94, Iss. 4, pp. 290-299
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis
Alba Grifoni, Tonino Alonzi, Galit Alter, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 53
Late-onset multiple sclerosis: disability trajectories in relapsing–remitting patients of the Italian MS Registry
Lorena Lorefice, Ottavia Elena Ferraro, Giuseppe Fenu, et al.
Journal of Neurology (2024) Vol. 271, Iss. 4, pp. 1630-1637
Closed Access | Times Cited: 7
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies
Luca Prosperini, Shalom Haggiag, Serena Ruggieri, et al.
CNS Drugs (2023) Vol. 37, Iss. 10, pp. 915-927
Closed Access | Times Cited: 13
Management of multiple sclerosis in older adults: review of current evidence and future perspectives
Kimberly DiMauro, Carol Swetlik, Jeffrey A. Cohen
Journal of Neurology (2024) Vol. 271, Iss. 7, pp. 3794-3805
Open Access | Times Cited: 4
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
Serena Ruggieri, Alessandra Aiello, Carla Tortorella, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8525-8525
Open Access | Times Cited: 10
Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis
Amy Perrin Ross, Jacqueline Nicholas, Ming-Hui Tai, et al.
BMC Neurology (2025) Vol. 25, Iss. 1
Open Access
Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
Hannah Solchenberger, Marcus Odendahl, Dirk Schriefer, et al.
Pathogens (2025) Vol. 14, Iss. 3, pp. 235-235
Open Access
Effective preparation and immunogenicity analysis of antigenic proteins for prevention of porcine enteropathogenic coronaviruses PEDV/TGEV/PDCoV
Xinhao Jia, Hang Liu, Y P Sun, et al.
International Journal of Biological Macromolecules (2025), pp. 142394-142394
Closed Access
Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study
Filipa Ladeira, Cláudia Nóbrega, João Cerqueira
Journal of Neurology (2025) Vol. 272, Iss. 4
Open Access
Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive Therapies
Mario Ferraioli, Alessandra Aiello, I. Prevete, et al.
Vaccines (2025) Vol. 13, Iss. 4, pp. 396-396
Open Access
Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases
Tonino Alonzi, Alessandra Aiello, Michela Sali, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117153-117153
Open Access | Times Cited: 3
Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination
Alessandra Aiello, Serena Ruggieri, Assunta Navarra, et al.
Vaccines (2024) Vol. 12, Iss. 8, pp. 926-926
Open Access | Times Cited: 3
SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel
Annapaola Santoro, Andrea Capri, Daniele Petrone, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1247-1247
Open Access | Times Cited: 8
Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV‐2 booster vaccination in hematologic neoplasms
Moraima Jiménez, Candela Fernández‐Naval, Vı́ctor Navarro, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1204-1213
Closed Access | Times Cited: 7
Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune-modifying therapies
Samuel D. Klebanoff, Lauren B. Rodda, Chihiro Morishima, et al.
JCI Insight (2023) Vol. 8, Iss. 15
Open Access | Times Cited: 6
Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination
Ilya Kister, Ryan Curtin, Amanda L. Piquet, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 7, pp. 1750-1764
Open Access | Times Cited: 2
Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders
Mohammad Yazdan Panah, Saeed Vaheb, Yousef Mokary, et al.
Vaccine (2024) Vol. 42, Iss. 23, pp. 126061-126061
Closed Access | Times Cited: 1
Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review
Federico Carlini, Valeria Lusi, Caterina Rizzi, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 5, pp. 1477-1490
Open Access | Times Cited: 3
The impact of hybrid immunity on immune responses after SARS‐CoV‐2 vaccination in persons with multiple sclerosis treated with disease‐modifying therapies
Monika Rabenstein, Olivia G. Thomas, Giorgia Carlin, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 12, pp. 3789-3798
Open Access | Times Cited: 3
Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma
Léa Da Silva, Timothée Klopfenstein, Vincent Gendrin, et al.
Viruses (2023) Vol. 15, Iss. 11, pp. 2220-2220
Open Access | Times Cited: 3
Humoral and Cellular Immune Response Elicited by Two Doses of mRNA BNT162b2 Vaccine Against SARS-CoV-2 in People Living with HIV
Claudia Vanetti, Laura Milazzo, Francesco Ardizzone, et al.
AIDS Research and Human Retroviruses (2023) Vol. 39, Iss. 9, pp. 495-499
Closed Access | Times Cited: 2
Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study
Michaela Koehm, Maximilian Klippstein, Stephanie Dauth, et al.
RMD Open (2023) Vol. 9, Iss. 3, pp. e003094-e003094
Open Access | Times Cited: 2
Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load
Cynthia L. Swan, Valentine Dushimiyimana, Pacifique Ndishimye, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107959-107959
Open Access | Times Cited: 1
Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination
Ilya Kister, Ryan Curtin, Amanda L. Piquet, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
A case study: ADEM-like lesions as a first clinical event in highly active multiple sclerosis
Vinicius Gabriel Coutinho Costa, Jéssica Vasques Raposo-Vedovi, Renan Amphilophio Fernandes, et al.
Research Square (Research Square) (2024)
Open Access
Page 1 - Next Page

Scroll to top